SecBot SecBot
Insider Cluster (2 insiders) ·Filed Apr 15, 2026

CYTK

CYTOKINETICS INC
BEARISH
Impact 7/10
Horizondays Processed7mo ago
Insider cluster: 2 insiders, $982K total
Actionable Insight ▼ Bearish

Traders should watch for potential downward pressure on the stock; coordinated C-suite selling at high magnitude relative to typical patterns may indicate private concerns about valuation or upcoming catalysts. Monitor for further filings or news that could clarify intent.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$65.42
T+0 close · Apr 15, 2026 · via day close
Latest settled
+25.24%
T+60 · $81.93
Vs SPY
+18.09%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 16 $65.42entry
  2. T+1 · 7mo ago +1.97%α +0.76% · $66.71
  3. T+5 · 7mo ago +0.09%α −0.88% · $65.48
  4. T+20 · 6mo ago +20.21%α +13.58% · $78.64
  5. T+60 · 4mo ago +25.24%α +18.09% · $81.93
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Two top executives at Cytokinetics, including the CEO and Chief Commercial Officer, sold nearly $1 million in shares over a single day, with both transactions occurring at market prices. This coordinated open-market selling by C-suite leaders signals potential lack of confidence in near-term prospects despite no disclosed negative news.

Key Financial Metrics

Direction
selling
Total Value
$982.1K
Insiders
2

Key Facts

  • CEO Robert Blum sold 7,500 shares for $490,350 at $65.38 per share on April 15, 2026
  • EVP Andrew Callos sold 7,449 shares for $491,782.98 at $66.02 per share on April 15, 2026
  • Total insider selling in the cluster: $982,132.98 over a 7-day window
  • Both transactions were open-market sales (code S), not tax-related or automatic disposals

Financial Impact

$982,133 in open-market share sales by two C-suite executives

insider ownershipinvestor sentiment

Risk Factors

  • Perception of insider pessimism could erode investor confidence
  • Potential for follow-on selling if other insiders act similarly

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-CYTK-1776288585732

Track record

46 reports on CYTK

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
  2. Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  4. Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
  5. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  6. Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
  7. Nov 4, 202612d ago 8-K Bullish 6/10 No price data
  8. Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
  9. Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
  10. Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
Showing 10 of 46

US Market Status

Market Closed · Opens Wed (11h 27m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 15, 2026